In spite of this company being potentially one of the major...

In spite of this company being potentially one of the major 'bagging' companies on the ASX, long term holders have repeatedly been disappointed with SP progress. Many of us have been struggling with low revenue, but also the frustration that TK refuses to give revenue guidance. Yet, he is happy to tell Alan Kohler:
We don’t provide any guidance on the future of those cash flow in that business, it’s still really too early to say. We obviously have some initial partnerships with Europe and Indonesia and Australia, we’re starting to generate revenue. But as you identified earlier, it’s about the adoption by clinicians, it’s about adoption by patients… There’s still a lot of variables that are playing into the adoption of the technology. Right now, we’re getting quite excited about how our revenue is growing over the last month. You referenced the last quarter, this quarter will come out next month and we’re really quite excited about that trajectory, but at this point in time it’s really hard to say.

Why couldn't he have said that in the Conference call? That aside, the fact that he is stating this means we may get some boost to the SP soon.

If we do partner up with a major health company, that could be another catalyst to give the SP the hurry up. Further international recognition. It would be a travesty if a preditor swoops on us, or would it? One preditor may mean many others just behind them, and further recognition on a world stage.

We have been going it alone all these years with lots achieved, but very little revenue. Continuation on this path will continue to frustrate us IMO. We need an international partner and it's clout to move up in a distrustful medical world.